Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract - PubMed (original) (raw)

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract

W S Gallichan et al. J Immunol. 2001.

Abstract

Development of vaccines capable of preventing the transmission or limiting the severity of sexually transmitted viruses, such as HSV and HIV, will likely be dependent on the induction of potent long-lasting mucosal immune responses in the genital tract. Recently, synthetic oligodeoxynucleotides (ODN) containing immunostimulatory CpG motifs were shown to serve as potent adjuvants for the induction of mucosal immune responses. Here, we show that intranasal immunization with CpG ODN, plus recombinant glycoprotein B (rgB) of HSV-1, results in significantly elevated levels of specific anti-gB IgA Abs in vaginal washes that remained high throughout the estrous cycle. Additionally, dramatically elevated numbers of specific IgA Ab-secreting cells were present and persisted in the genital tract in response to intravaginal (IVAG) HSV-2 challenge. HSV-2-specific CTL were observed at moderate levels in the spleens of CpG or non-CpG ODN-immunized mice. In contrast, strong CTL responses were observed locally in the genital tissues of both groups following IVAG HSV-2 challenge. Interestingly, mice immunized intranasally with rgB plus CpG ODN, but not non-CpG ODN, were significantly protected following IVAG HSV-2 challenge. Measurement of virus in protected CpG-immunized mice revealed a log lower level of replication within the first few days after infection. In conclusion, these results indicate that intranasal immunization with CpG ODN plus protein mediates immunity in the female genital tract capable of protecting against a sexually transmitted pathogen.

PubMed Disclaimer

Cited by

Unraveling the gut-Lung axis: Exploring complex mechanisms in disease interplay.
Eladham MW, Selvakumar B, Saheb Sharif-Askari N, Saheb Sharif-Askari F, Ibrahim SM, Halwani R. Eladham MW, et al. Heliyon. 2024 Jan 3;10(1):e24032. doi: 10.1016/j.heliyon.2024.e24032. eCollection 2024 Jan 15. Heliyon. 2024. PMID: 38268584 Free PMC article. Review.
Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens.
Dotiwala F, Upadhyay AK. Dotiwala F, et al. Vaccines (Basel). 2023 Oct 12;11(10):1585. doi: 10.3390/vaccines11101585. Vaccines (Basel). 2023. PMID: 37896988 Free PMC article. Review.
The lung-gut crosstalk in respiratory and inflammatory bowel disease.
Du B, Fu Y, Han Y, Sun Q, Xu J, Yang Y, Rong R. Du B, et al. Front Cell Infect Microbiol. 2023 Aug 23;13:1218565. doi: 10.3389/fcimb.2023.1218565. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37680747 Free PMC article. Review.
Establishment of isotype-switched, antigen-specific B cells in multiple mucosal tissues using non-mucosal immunization.
Prior JT, Limbert VM, Horowitz RM, D'Souza SJ, Bachnak L, Godwin MS, Bauer DL, Harrell JE, Morici LA, Taylor JJ, McLachlan JB. Prior JT, et al. NPJ Vaccines. 2023 May 31;8(1):80. doi: 10.1038/s41541-023-00677-z. NPJ Vaccines. 2023. PMID: 37258506 Free PMC article.
New-age vaccine adjuvants, their development, and future perspective.
Verma SK, Mahajan P, Singh NK, Gupta A, Aggarwal R, Rappuoli R, Johri AK. Verma SK, et al. Front Immunol. 2023 Feb 24;14:1043109. doi: 10.3389/fimmu.2023.1043109. eCollection 2023. Front Immunol. 2023. PMID: 36911719 Free PMC article. Review.

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract - PubMed (original) (raw)